Program in Developmental Endocrinology and Genetics, Section on Molecular Dysmorphology, NICHD, NIH, DHHS, Bld. 10, Rm. 9D42, 10 Center Dr, Bethesda, MD, 20892, USA.
J Inherit Metab Dis. 2014 Jan;37(1):83-92. doi: 10.1007/s10545-013-9610-6. Epub 2013 May 8.
Niemann-Pick disease, type C1 (NPC1) is an autosomal recessive lipid storage disorder in which a pathological cascade, including neuroinflammation occurs. While data demonstrating neuroinflammation is prevalent in mouse models, data from NPC1 patients is lacking. The current study focuses on identifying potential markers of neuroinflammation in NPC1 from both the Npc1 mouse model and NPC1 patients. We identified in the mouse model significant changes in expression of genes associated with inflammation and compared these results to the pattern of expression in human cortex and cerebellar tissue. From gene expression array analysis, complement 3 (C3) was increased in mouse and human post-mortem NPC1 brain tissues. We also characterized protein levels of inflammatory markers in cerebrospinal fluid (CSF) from NPC1 patients and controls. We found increased levels of interleukin 3, chemokine (C-X-C motif) ligand 5, interleukin 16 and chemokine ligand 3 (CCL3), and decreased levels of interleukin 4, 10, 13 and 12p40 in CSF from NPC1 patients. CSF markers were evaluated with respect to phenotypic severity. Miglustat treatment in NPC1 patients slightly decreased IL-3, IL-10 and IL-13 CSF levels; however, further studies are needed to establish a strong effect of miglustat on inflammation markers. The identification of inflammatory markers with altered levels in the cerebrospinal fluid of NPC1 patients may provide a means to follow secondary events in NPC1 disease during therapeutic trials.
尼曼-匹克病 C 型 1 型(NPC1)是一种常染色体隐性脂质贮积病,其中包括神经炎症在内的病理级联反应发生。虽然有数据表明神经炎症在小鼠模型中普遍存在,但 NPC1 患者的数据却缺乏。本研究重点在于从 NPC1 患者和 Npc1 小鼠模型中鉴定 NPC1 中神经炎症的潜在标志物。我们在小鼠模型中鉴定出与炎症相关的基因表达发生显著变化,并将这些结果与人类大脑皮质和小脑组织的表达模式进行比较。通过基因表达谱分析,发现补体 3(C3)在小鼠和 NPC1 患者死后脑组织中增加。我们还对 NPC1 患者和对照组的脑脊液(CSF)中炎症标志物的蛋白水平进行了特征描述。我们发现 NPC1 患者的 CSF 中白细胞介素 3、趋化因子(C-X-C 基序)配体 5、白细胞介素 16 和趋化因子配体 3(CCL3)水平升高,白细胞介素 4、10、13 和 12p40 水平降低。CSF 标志物的评估与表型严重程度有关。米格列醇治疗 NPC1 患者后,CSF 中 IL-3、IL-10 和 IL-13 水平略有降低;然而,仍需要进一步的研究来确定米格列醇对炎症标志物的强烈影响。鉴定 NPC1 患者脑脊液中水平改变的炎症标志物可能为在治疗试验中追踪 NPC1 疾病的继发性事件提供一种手段。